Incidence and consequences of bone metastases in lung cancer patients

Journal of Bone Oncology

Volumn 2, Issue 1, 2013, Pages 22-29

  Kuchuk, Michael ^a   Addison, Christina L ^b,c   Clemons, Mark ^a,b   Kuchuk, Iryna ^a   Wheatley Price, Paul ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bisphosphonates and denosumab; Bone metastasis; Non small cell lung cancer; Skeletal related event

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER INCIDENCE; CANCER PAIN; CANCER PATIENT; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION;

EID: 84882428439     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.12.004     Document Type: Article

References (66)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012;62: 10-29.
2. Yu JL, Simmons C, Victor JC, Han D, Hogeveen S, Leighl N, et al. Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. The Oncologist 2011;16: 1307-15.
3. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer (Amsterdam, Netherlands) 2007;57: 229-32. (Pubitemid 47044952)
4. Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. The Annals of Thoracic Surgery 1996;62: 246-50. (Pubitemid 26239872)
5. Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung - a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncologica (Stockholm, Sweden) 1997;36: 301-6. (Pubitemid 27232332)
6. Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. International Orthopaedics 1989;13: 119-23. (Pubitemid 19147165)
7. Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer (Amsterdam, Netherlands) 2011;71: 89-93.
8. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69: 1-18. (Pubitemid 27081402)
9. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2011;6: 576-82.
10. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67: 390-6.
11. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. European Journal of Cancer Care 2010;19: 755-60.
12. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2006;1: 571-6. (Pubitemid 47181406)
13. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003;21: 3150-7. (Pubitemid 46606297)
14. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100: 2613-21. (Pubitemid 38715767)
15. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clinical Lung Cancer 2004;6: 170-4. (Pubitemid 39618641)
16. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2008;3: 228-36. (Pubitemid 351654321)
17. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011;29: 1125-32.
18. Mathew A, Rosenzweig MQ, Brufsky A. Association between bisphosphonate use in metastatic breast cancer (MBC) and overall survival. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011;29.
19. Nieder C, Haukland E, Pawinski A, Dalhaug A. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urology 2010;10: 23.
20. Henk HJ, Kaura S. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. Journal of Medical Economics 2012;15: 185-94.
21. Osada H, Nakajima Y, Taira Y, Yokote K, Noguchi T. The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer. The Japanese Journal of Surgery 1987;17: 362-8. (Pubitemid 18056044)
22. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990;97: 1052-8. (Pubitemid 20166789)
23. Michel F, Soler M, Imhof E, Perruchoud AP. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991;46: 469-73.
24. Tornyos K, Garcia O, Karr B, LeBeaud R. A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer. Clinical Nuclear Medicine 1991;16: 107-9.
25. Kosteva J, Langer C. Incidence and distribution of skeletal metastases in NSCLC in the era of PET [abstract]. Lung Cancer 2004;46: S45.
26. Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clinical Orthopaedics and Related Research 2008;466: 729-36.
27. Spizzo G, Seeber A, Mitterer M. Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Research 2009;29: 5245-9.
28. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer (Amsterdam, Netherlands) 2009;65: 219-22.
29. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010;60: 277-300.
30. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. International Journal of Clinical Practice 2003;57: 184-6. (Pubitemid 36511776)
31. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. The Oncologist 2011;16: 155-64.
32. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. British Journal of Cancer 1987;55: 61-6. (Pubitemid 17234155)
33. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110: 1860-7. (Pubitemid 47557312)
34. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2004;15: 455-9. (Pubitemid 38444549)
35. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer (Amsterdam, Netherlands) 2012.
36. De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2009;4: 1280-8.
37. Hatoum HT, Lin S, Lipton A, Barghout V, Mody-Patel N, Smith MR. The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on followup duration post diagnosis of bone metastasis in lung cancer patients. Journal of Clinical Oncology 2008;26.
38. Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Research and Treatment 2011;129: 495-503.
39. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. The Journal of Urology 2002;168: 1005-7.
40. Yoshida T, Yoh K, Goto K, Umemura S, Niho S, Ohmatsu H, et al. Impact of EGFR tyrosine kinase inhibitors on skeletal-related events in EGFR mutation-positive non-small cell lung cancer patients with bone metastases. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012;30.
41. Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, Normanno N. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer (Amsterdam, Netherlands) 2008;60: 452-4.
42. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Research and Treatment 2005;89: 165-72. (Pubitemid 40249050)
43. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical Oncology (Royal College of Radiologists (Great Britain)) 2012;24: 112-24.
44. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. International Journal of Radiation Oncology, Biology, Physics 2003;55: 594-605. (Pubitemid 36170000)
45. Haddad P, Wong RK, Pond GR, Soban F, Williams D, McLean M, et al. Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clinical Oncology (Royal College of Radiologists (Great Britain)) 2005;17: 430-4. (Pubitemid 41136138)
46. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88: 1082-90. (Pubitemid 30127670)
47. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. The New England Journal of Medicine 1996;335: 1785-91. (Pubitemid 26412396)
48. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001;19: 558-67. (Pubitemid 32112871)
49. Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Current Opinion in Endocrinology, Diabetes, and Obesity 2011;18: 339-46.
50. Dino Amadori MA, Alessi Barbara, Gianni Lorenzo, Ibrahim Toni, Farina Gabriella, Gaion Fernando, et al. Roberta Rondena, Paola Bogani, Carla Ripamonti. ZOOM: a prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012;30.
51. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010;28: 5132-9.
52. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98: 1735-44. (Pubitemid 37238631)
53. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. Journal of Experimental & Clinical Cancer Research: CR 1998;17: 213-7. (Pubitemid 28335581)
54. Kiagia M, Karapanagiotou E, Charpidou A, Dilana K, Dionellis G, Dannos I, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Research 2006;26: 3133-6. (Pubitemid 44161812)
55. Mystakidou K, Stathopoulou E, Parpa E, Kouloulias V, Kouskouni E, Vlahos L. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. Journal of Cancer Research and Clinical Oncology 2008;134: 1303-10.
56. Heras P, Hatzopoulos A, Heras V, Kritikos N, Karagiannis S, Kritikos K. A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. American Journal of Therapeutics 2011;18: 340-2.
57. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. International Journal of Cancer Journal International du Cancer 2009;125: 1705-9.
58. Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2010;67: 330-8.
59. Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2012.
60. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Maingold C, Solal-Seligny P, Rodriguez G, Krzakovski M, Mehta ND, Lipton L, Garcia-Saenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. Journal of Thoracic Oncology 2012;7(12): 1823-9.
61. Henk HJ, Kaura S, Teitelbaum A. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. Journal of Medical Economics 2012;15: 195-204.
62. Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. Journal of Thoracic oncology: Official Publication of the International Association for the Study of Lung Cancer 2011;6: 1030-8.
63. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 2011;12: 735-42.
64. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine 2010;362: 2380-8.
65. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 2010;11: 121-8.
66. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology 2012;13: 239-46.